Clinical Trial Update: Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 safety study evaluating gene-modified donor T-cells after TCRαβ+ depleted stem cell transplant was terminated; results were posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Anemia Aplastic
• Anemia Sickle Cell
• Cytopenia
• Diamond-blackfan Anemia
• Fanconi Anemia
• Hemoglobinopathies
• Immunodeficiency
• Leukemia Acute Myeloid
• Lymphoma Non-hodgkin
• Myelodysplastic Syndrome
• Osteopetrosis
• Thalassemia

Drugs mentioned

• Bellicum gene-modified donor T-cells
• TCRαβ+ depleted stem cell transplant

Snippet

Sponsor: Bellicum Pharmaceuticals | Conditions: Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-01-04